Differential in vitro effects of chemotherapeutic agents on primary cultures of human ovarian carcinoma

International Journal of Gynecological Cancer

Volumn 14, Issue 4, 2004, Pages 607-615

  Kornblith, Paul ^a,c   Ochs, R L ^a   Wells, A ^b   Gabrin, M J ^a   Piwowar, J ^a   Chattopadhyay, A ^a   George, L D ^a   Burholt, D ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Precision Therapeutics Inc   (United States)

Author keywords

Chemoresponse testing; Chemotherapy; Ovarian cancer; Primary cell culture

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONCENTRATION RESPONSE; DRUG POTENCY; EXPLANT; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELLS, CULTURED; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 4043092805     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1048-891X.2004.14408.x     Document Type: Article

References (36)

1. Ozols RF. Chemotherapy of ovarian cancer. In: Ozols RF, ed. Gynecologic Oncology. Boston: Kluwer Academic Publishers, 1998, 219-34.
2. Ness RB, Wisniewski SR, Eng H, Christopherson W. Cell viability assay for drug testing in ovarian cancer: in vitro kill versus clinical response. Anticancer Res 2002;22:1145-9.
3. Kornblith P, Wells A, Gabrin MJ et al. In vitro responses of ovarian cancer to platinums and taxanes. Anticancer Res 2003;23:543-8.
4. Chu E, DeVita VT Jr. Principles of cancer management: chemotherapy, in vitro drug response assays. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott Williams & Wilkins, 2001, 302-4.
5. Goldie JH, Coldman AJ. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 1984;44:3643-53.
6. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989;58:137-71.
7. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991;66:85-94.
8. Kornblith P, Wells A, Gabrin MJ et al. Breast cancer-response rates to chemotherapeutic agents studied in vitro. Anticancer Res 2003;23:3405-12.
9. Fruehauf JP, Bosanquet AG. In vitro determination of drug response: a discussion of clinical applications. PPO 1993;7:1-16.
10. Fruehauf JP. In vitro assay-assisted treatment selection for women with breast or ovarian cancer. Endocr Relat Cancer 2002;9:171-82.
11. Andreotti PE, Cree IA, Kurbacher KM et al. Chemo-sensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995;55:5276-82.
12. O'Meara AT, Sevin B-U. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer. Gynecol Oncol 2001;83:334-42.
13. Singh B, Li R, Xu L et al. Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 2002;24:437-42.
14. Kobayashi H, Tanisaka K, Doi O et al. An in vitro chemosensitivity test for solid human tumors using collagen gel droplet embedded cultures. Int J Oncol 1997;11:449-55.
15. Nagourney RA, Brewer CA, Radecki S et al. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol 2003;88:35-9.
16. Ochs RL, Fensterer J, Ohori NP et al. Evidence for the isolation, growth, and characterization of malignant cells in primary cultures of human tumors. In Vitro Cell Dev Biol Anim 2003;39:63-70.
17. Aabo K, Hald I, Horbov S et al. A randomized study of single agent vs combination chemotherapy in FIGO stages IIB, III and IV ovarian adenocarcinoma. Eur J Cancer Clin Oncol 1985;21:475-81.
18. Lambert HE, Berry RJ. High dose cisplatin compared with high dose cyclophosphamide in the management of advanced epithelial ovarian cancer (FIGO stages III and IV): report from the North Thames Cooperative Group. Br Med J (Clin Res Ed) 1985;290:889-93.
19. Carmo-Pereira J, Costa FO, Henriques E, Ricardo JA. Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF). Cancer 1981;48:1947-51.
20. Gordon AN, Granai CO, Rose PG et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000; 18:3093-100.
21. Israel VP, Garcia AA, Roman L et al. Phase II study of liposomal doxorubicin in advanced gynecologic cancers. Gynecol Oncol 2000;78:143-7.
22. Muggia FM, Hainsworth JD, Jeffers S et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997;15:987-93.
23. de Palo GM, de Lena M, Di Re F, Luciani L, Valagussa P, Bonadonna G. Melphalan versus adriamycin in the treatment of advanced carcinoma of the ovary. Surg Gynecol Obstet 1975;141:899-902.
24. de Wit R, van der Burg ME, van den Gaast A, Logmans A, Stoter G, Verweij J., Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy. Ann Oncol 1994;5:656-7.
25. Kuhn W, Schmalfeldt B, Dose J et al. Intravenous or oral etoposide therapy of platinum refractory ovarian cancer with early recurrence. Results of a prospective randomized study. Geburtshilfe Frauenheilkd 1996;56:105-10.
26. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998;16:405-10.
27. Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 1994;12:60-3.
28. Seymour MT, Mansi JL, Gallagher CJ et al. Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer 1994;69:191-5.
29. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994;86:1530-3.
30. Underhill CR, Parnis FX, Highley MS et al. Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer. Anti-cancer Drugs 2001;12:647-52.
31. von Minckwitz G, Bauknecht T, Visseren-Grul CM, Neijt JP. Phase II study of gemcitabine in ovarian cancer. Ann Oncol 1999;10:853-5.
32. Bookman MA, Malmstrom H, Bolis G et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998;16:3345-52.
33. Creemers GJ, Bolis G, Gore M et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996;14:3056-61.
34. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-22.
35. Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 1997;66:480-6.
36. ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183-93.